Honors and Awards
• 1989-1990 - Gillette Fellow, Medical Engineering and Medical Physics, Harvard-MIT, Cambridge, MA
• 1993-1994 - Sterling Winthrop Fellow, Health Sciences and Technology, Harvard-MIT, Cambridge, MA
• 1998 - Featured in Milwaukee Business Journal's "40 Under 40"
• 1999 - American Society of Neuroradiology Meeting, Magna Cum Laude, awarded to "Diffusion magnetic resonance imaging in stroke: A comparison of spin-echo and FLAIR spin echo diffusion sensitive techniques," JL Ulmer, AT Olson, LL Latour, OB Nordling, KM Donahue
• 2001 - 101st Annual Scientific Meeting of American Roentgen Ray Society, Seattle, Washington, Scientific Exhibit Gold Medal awarded to "Physiologic magnetic resonance imaging of the brain: A conceptual approach to contrast mechanisms and measureable physiologic parameters," JL Ulmer, JM Strottmann, RW Prost, KM Schmainda, BB Biswal, LP Mark, DL Daniels
• 2004 - International Society of Magnetic Resonance in Medicine Meeting, Young Investigator Moore Award, awarded to "Intravoxel distribution of DWI decay rates reveals C6 glioma invasion in rat brain," *KM Bennett, JS Hyde, SD Rand, R Bennett, HGJ Krouwer, KJ Rebro, KM Schmainda
• 2004 - International Society of Magnetic Resonance in Medicine Meeting, First Place Poster Award, Cancer Imaging and Spectroscopy, awarded to "The anti-angiogenic drug, SU11657 decreases brain tumor size and normalizes perfusion as indicated by DSC-MRI perfusion parameters," *CC Quarles, FC Wu, M Darpolor, SD Rand, HGJ Krouwer, KM Schmainda
• 2004 - American Society of Neuroradiology Meeting, Summa Cum Laude, awarded to "Lesion-induced neurovascular uncoupling can mimic cortical reorganization by BOLD fMRI," JL Ulmer, L Hacein-Bey, VP Mathews, EA DeYoe, RW Prost, KM Schmainda, WM Mueller, HGJ Krouwer
*Student of Dr. Kathleen Schmainda
• MRI Contrast Agent Methods to Assess Tumor Angiogenesis is a five-year award from the National Cancer Institute. The objective of this work is to develop and validate contrast agent MRI methods for the evaluation of tumor angiogenesis and anti-angiogenic therapies. (Dr. Alan Bloom, PI) is a one-year award from the MCW Cancer Center's State of Wisconsin Tax Check-Off Program and the New Initiative in Breast Cancer Research. The primary goal of this grant is to evaluate with functional imaging the cognitive effects of chemotherapy in breast cancer patients.
• Diffusion MRI to Detect Glioma Invasion is a two-year award from the National Cancer Institute. The objective of this work is to develop and validate diffusion-based MRI methods to detect invading glioma cells.
• Effects of Chemotherapy on Cognition and Brain Function in Breast Cancer Patients
Completed Research Support
• Development of an MRI Method to Measure Breast Tumor Blood Volume: A Sensitive and Specific Indicator of Breast Cancer was a two-year award from the Wisconsin Breast Cancer Showhouse. The primary goal of this grant was to evaluate the feasibility and utility of dynamic susceptibility contrast agent methods to measure breast tumor blood volume.
• Facilitating Discovery with Multi-Parameter Physiologic Imaging of Brain Tumors is a two-year award from the Medical College of Wisconsin's Advancing a Healthier Wisconsin program. The primary goal of this grant was to facilitate the translation of advanced, multifunctional brain tumor MRI tools into the clinic through the development of a brain-tumor imaging platform.
• Analysis of rCBV Data (Berlex Laboratories) supported the analysis and collection of rCBV data for purposes of designing a phase III clinical trial of a new contrast agent.
• Mito-Q Attentuates DOX-Induced Cardiotoxicity and Potentiates Antitumor Effects: MR imaging and Echocardiography Studies (Dr. Balaraman Kalyanaraman, PI) is a two-year award from the Wisconsin Breast Cancer Showhouse. The primary goal of this grant was to evaluate with imaging the effects of Mito-Q.